Form 8-K - Current report:
SEC Accession No. 0001437749-24-036441
Filing Date
2024-12-02
Accepted
2024-12-02 14:54:28
Documents
14
Period of Report
2024-12-02
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K inbp20241202_8k.htm   iXBRL 8-K 46841
  Complete submission text file 0001437749-24-036441.txt   168555

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA inbp-20241202.xsd EX-101.SCH 3409
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inbp-20241202_def.xml EX-101.DEF 10353
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inbp-20241202_lab.xml EX-101.LAB 13836
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inbp-20241202_pre.xml EX-101.PRE 10348
16 EXTRACTED XBRL INSTANCE DOCUMENT inbp20241202_8k_htm.xml XML 2551
Mailing Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205
Business Address 225 LONG AVENUE BUILDING 15 HILLSIDE NJ 07205 9739260816
INTEGRATED BIOPHARMA INC (Filer) CIK: 0001016504 (see all company filings)

EIN.: 222407475 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-31668 | Film No.: 241518537
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)